Ernexa Therapeutics Inc. Share-based Payment Arrangement, Expense, after Tax
Ernexa Therapeutics Inc. (ERNA) reported Share-based Payment Arrangement, Expense, after Tax of $68.00 thousand for the 3-month period ending 2014-09-30, per its 10-Q filed 2014-11-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax · last filed 2014-11-07
- Ernexa Therapeutics Inc. share-based payment arrangement, expense, after tax for the quarter ending 2014-09-30 was $68.00K, a 100.00% increase year-over-year.
- Ernexa Therapeutics Inc. share-based payment arrangement, expense, after tax for the quarter ending 2014-06-30 was $60.00K, a 122.22% increase year-over-year.
- Ernexa Therapeutics Inc. share-based payment arrangement, expense, after tax for the quarter ending 2014-03-31 was $52.00K, a 100.00% increase year-over-year.
- Ernexa Therapeutics Inc. share-based payment arrangement, expense, after tax for the quarter ending 2013-09-30 was $34.00K, a 30.77% increase year-over-year.
- Ernexa Therapeutics Inc. share-based payment arrangement, expense, after tax for fiscal 2012 was $185.00K, a 44.28% decline from fiscal 2011.
- Ernexa Therapeutics Inc. share-based payment arrangement, expense, after tax for fiscal 2011 was $332.00K.
| Period end | Share-based Payment Arrangement, Expense, after Tax 3 month | Share-based Payment Arrangement, Expense, after Tax 6 month | Share-based Payment Arrangement, Expense, after Tax 9 month | Share-based Payment Arrangement, Expense, after Tax 12 month |
|---|---|---|---|---|
| 2014-09-30 | $68.00K 10-Q · filed 2014-11-07 | $128.00K derived: sum of 2 quarters · filed 2014-11-07 | $180.00K 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $60.00K 10-Q · filed 2014-08-14 | $111.00K 10-Q · filed 2014-08-14 | ||
| 2014-03-31 | $52.00K 10-Q · filed 2014-05-15 | |||
| 2013-09-30 | $34.00K 10-Q · filed 2014-11-07 | $61.00K derived: sum of 2 quarters · filed 2014-11-07 | $87.00K 10-Q · filed 2014-11-07 | $109.00K derived: sum of 4 quarters · filed 2014-11-07 |
| 2013-06-30 | $27.00K 10-Q · filed 2014-08-14 | $53.00K 10-Q · filed 2014-08-14 | $75.00K derived: sum of 3 quarters · filed 2014-08-14 | $101.00K derived: sum of 4 quarters · filed 2014-08-14 |
| 2013-03-31 | $26.00K 10-Q · filed 2014-05-15 | $48.00K derived: sum of 2 quarters · filed 2014-05-15 | $74.00K derived: sum of 3 quarters · filed 2014-05-15 | $134.00K derived: sum of 4 quarters · filed 2014-05-15 |
| 2012-12-31 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-29 | $48.00K derived: sum of 2 quarters · filed 2013-11-14 | $108.00K derived: sum of 3 quarters · filed 2013-11-14 | $185.00K 10-K · filed 2013-03-29 |
| 2012-09-30 | $26.00K 10-Q · filed 2013-11-14 | $86.00K derived: sum of 2 quarters · filed 2013-11-14 | $163.00K 10-Q · filed 2013-11-14 | $254.00K derived: sum of 4 quarters · filed 2013-11-14 |
| 2012-06-30 | $60.00K 10-Q · filed 2013-08-14 | $137.00K 10-Q · filed 2013-08-14 | $228.00K derived: sum of 3 quarters · filed 2013-08-14 | $316.00K derived: sum of 4 quarters · filed 2013-08-14 |
| 2012-03-31 | $78.00K 10-Q · filed 2013-05-13 | $168.00K derived: sum of 2 quarters · filed 2013-05-13 | $256.00K derived: sum of 3 quarters · filed 2013-05-13 | $339.00K derived: sum of 4 quarters · filed 2013-05-13 |
| 2011-12-31 | $90.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-29 | $178.00K derived: sum of 2 quarters · filed 2013-03-29 | $261.00K derived: sum of 3 quarters · filed 2013-03-29 | $332.00K 10-K · filed 2013-03-29 |
| 2011-09-30 | $88.00K 10-Q · filed 2012-11-09 | $171.00K derived: sum of 2 quarters · filed 2012-11-09 | $242.00K 10-Q · filed 2012-11-09 | |
| 2011-06-30 | $83.00K 10-Q · filed 2012-08-14 | $154.00K 10-Q · filed 2012-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |